Traffic Lights - Latest Updates

Last updated: 05/06/2020

Other updates on this site
Drug Name Classification Clinical Indication Comments
ACETYLCYSTEINE EFFERVESCENT TABLETS (NACYS®) (UPDATED) Green COPD Reduction of sputum viscosity

 

 

ALIROCUMAB (Praluent®) (NEW) Black Adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels

Not yet reviewed

BUPRENORPHINE PROLONGED RELEASE INJECTION (Buvidal®) (UPDATED) Red Substance misuse

Turning Point are piloting this in a small number of patients. If a patient is admitted to hospital contact turning point for advice about alternatives:

0116 3732117 – Direct dial to prescribing team

0116 3732108 – Direct Dial to Clinical Admin

0330 303 6000 – Main Switchboard

CANNABIDIOL(Epidyolex®) (UPDATED) Red Seizures associated with Dravet syndrome or Lennox-Gastaut syndrome in combination with clobazam

In line with NICE TA614 and NICE TA615

CLADRIBINE (UPDATED) Red Relapsing-remitting multiple sclerosis

In line with NICE TA616

CYANOCOBALAMIN (UPDATED) Black Vitamin B12

Initially for new patients only. Implementation date for all patients September 2020 to allow time for review. Exception to this traffic light is use as per Covid pandemic vitamin B12 advice

ELEXACAFTOR/IVACAFTOR/TEZACAFTOR (Trikafta®) (NEW) Red Cystic fibrosis as part of managed access programme

Also known as VX-445/VX-661/VX-770

GLYCOPYRRONIUM LIQUID (Colonis) (NEW) Amber Simple Sialorrhoea in paediatrics
MEROPENEM and Vaborbactam (Vaborem®) (NEW) Red Infections known/suspected to be caused by KPC producing bacteria
MEXILETINE (Namuscla®) (NEW) Black Symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic disorders

Not yet reviewed

NALOXONE nasal spray (Nyxoid®) (UPDATED) Red Opioid overdose

Turning Point Only

PARATHYROID HORMONE (Natpar®) (UPDATED) Red Post-trial continuation of treatment of chronic hypoparathyroidism when standard therapy alone is inadequate.
PATIROMER (Veltassa®) (UPDATED) Red Hyperkalaemia

In line with NICE TA623

PATISIRAN (Onpattro®) (NEW) Black Hereditary transthyretin-mediated amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy

Not yet reviewed

PEGINTERFERON BETA-1a (Plegridy®) (NEW) Red Relapsing-remitting multiple sclerosis

In line with NICE TA624

PENTOSAN POLYSULFATE SODIUM (Elmiron®) (UPDATED) Red Bladder pain syndrome characterised by either glomerulations or Hunner’s lesions

In line with NICE TA610

PRASTERONE PESSARY (Intrarosa®) (UPDATED) Amber Simple Vulvar and vaginal atrophy in postmenopausal women having moderate to severe symptoms
ROMOSOZUMAB SOLUTION FOR INJECTION (Evenity®) (NEW) Black Severe osteoporosis in postmenopausal women at high risk of fracture

Not yet reviewed

SODIUM ZIRCONIUM CYCLOSILICATE (Lokelma®) (UPDATED) Red Hyperkalaemia

In line with NICE TA599.

Implementation date 4th December 2019.

TERIPARATIDE (UPDATED) Red Osteoporosis in men and women
TEZACAFTOR AND IVACAFTOR (Symkevi ®) (NEW) Red Cystic Fibrosis
ULIPRISTAL ACETATE (Esmya ®) (UPDATED) Black Uterine fibroids

In line with MHRA alert March 2020 regarding risks of liver injury.

VSL#3 (UPDATED) Black Probiotic

Other Updates on this Website

Recent documents from LMSG and TAS


About the Leicestershire Medicines Strategy Group

In common with other local health communities, the Leicestershire Medicines Strategy Group (LMSG) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.

Leicestershire Health Community comprises the three Clinical Commissioning Groups, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LMSG has been in place since 2005. Learn more